Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders |
On June1, 2017, the Company held its Annual Meeting. Proxies for
the Annual Meeting were solicited by the Companys Board of
Directors to Section14(a) of the Securities Exchange Act of 1934,
as amended. Of the 28.8million outstanding shares of the Companys
common stock that could be voted at the Annual Meeting,
22.8million shares, or approximately 79%, were represented at the
Annual Meeting in person or by proxy, which constituted a quorum.
The following is a brief description of each matter voted upon at
the Annual Meeting, as well as the final tabulation of the number
of votes cast. A more complete description of each matter is set
forth in the Companys definitive proxy statement filed with the
Securities and Exchange Commission on April19, 2017.
| Proposal1: |
Each of the seven directors proposed by the Company for re-election was elected by the following votes to serve until the Companys 2018 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows: |
| For | Withheld | BrokerNon-Votes | ||||||||||
| Kieran T. Gallahue | 19,451,281 | 148,183 | 3,197,312 | |||||||||
| Lisa D. Earnhardt | 19,575,876 | 23,588 | 3,197,312 | |||||||||
| Cynthia L. Lucchese | 19,449,539 | 149,925 | 3,197,312 | |||||||||
| Dana G. Mead, Jr. | 19,427,010 | 172,454 | 3,197,312 | |||||||||
| Frederic H. Moll, M.D. | 19,448,329 | 151,135 | 3,197,312 | |||||||||
| Casey M. Tansey | 19,426,942 | 172,522 | 3,197,312 | |||||||||
| W. Anthony Vernon | 19,428,929 | 170,535 | 3,197,312 |
| Proposal2: |
The appointment of Ernst Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017 was ratified. The tabulation of votes on this matter was as follows: |
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
|
22,771,227 |
24,794 |
| Proposal3: |
The advisory vote on executive compensation as described in the Companys definitive proxy statement was approved. The tabulation of votes on this matter was as follows: |
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
|
19,275,548 |
315,047 | 8,869 | 3,197,312 |
About Intersect ENT, Inc. (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.
